home / stock / gnpx / gnpx quote
Last: | $2.21 |
---|---|
Change Percent: | -2.36% |
Open: | $2.17 |
Close: | $2.21 |
High: | $2.3292 |
Low: | $2.09 |
Volume: | 23,047 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.21 | $2.17 | $2.21 | $2.3292 | $2.09 | 23,047 | 04-26-2024 |
$2.12 | $2.24 | $2.12 | $2.24 | $2.11 | 8,625 | 04-25-2024 |
$2.21 | $2.27 | $2.21 | $2.32 | $2.13 | 19,635 | 04-24-2024 |
$2.31 | $2.21 | $2.31 | $2.5 | $2.18 | 30,284 | 04-23-2024 |
$2.163 | $2.29 | $2.163 | $2.38 | $2.12 | 19,446 | 04-22-2024 |
$2.13 | $2.23 | $2.13 | $2.5 | $2.09 | 38,192 | 04-19-2024 |
$2.2194 | $2.27 | $2.2194 | $2.27 | $2.18 | 17,493 | 04-18-2024 |
$2.21 | $2.35 | $2.21 | $2.542 | $2.2 | 20,749 | 04-17-2024 |
$2.3 | $2.39 | $2.3 | $2.45 | $2.27 | 20,368 | 04-16-2024 |
$2.35 | $2.77 | $2.35 | $2.77 | $2.35 | 32,896 | 04-15-2024 |
$2.68 | $2.78 | $2.68 | $2.8699 | $2.65 | 20,689 | 04-12-2024 |
$2.78 | $2.81 | $2.78 | $2.9122 | $2.74 | 16,842 | 04-11-2024 |
$2.88 | $3.03 | $2.88 | $3.03 | $2.73 | 49,924 | 04-10-2024 |
$3.07 | $3.03 | $3.07 | $3.23 | $2.9101 | 126,928 | 04-09-2024 |
$2.96 | $3.106 | $2.96 | $3.24 | $2.94 | 21,454 | 04-08-2024 |
$3 | $2.99 | $3 | $3.1786 | $2.97 | 17,583 | 04-05-2024 |
$2.99 | $3.15 | $2.99 | $3.18 | $2.96 | 44,470 | 04-04-2024 |
$3.11 | $2.89 | $3.11 | $3.27 | $2.89 | 97,702 | 04-03-2024 |
$2.84 | $2.8 | $2.84 | $3 | $2.7206 | 56,497 | 04-02-2024 |
$2.97 | $3 | $2.97 | $3.01 | $2.84 | 47,187 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting PR Newswire Compelling Data Validates the Potential...
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Multiple clinical trial sites to be opened under collaboration with large network of community-based oncol...
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizin...